Summary & Overview
HCPCS J2790: Rho(D) Immune Globulin Injection, Full Dose 300 mcg
HCPCS Level II code J2790 denotes a full-dose 300 microgram (1500 I.U.) injection of Rho(D) immune globulin, a human-derived product used to prevent Rh alloimmunization. Nationally, this code matters for obstetric, postpartum and certain urgent exposure scenarios where preventing maternal sensitization to Rh-positive fetal or donor red blood cells is clinically important. Proper coding affects clinical workflows, inventory control and payer adjudication for a time-sensitive prophylactic intervention.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a national overview of clinical context and common settings of care, descriptions of typical billing practices, and summaries of payer coverage considerations and reimbursement benchmarks where available. The publication highlights coding guidance, common modifiers in use, and areas where policy updates or prior authorization requirements can affect access and billing. It also outlines implications for supply chain and administration timing in outpatient and hospital-based settings.
Intended for billing managers, clinicians, and policy analysts, the piece presents actionable reference material on coding J2790, billing environments, and payer contexts to support accurate claim submission and program oversight.
Billing Code Overview
HCPCS Level II code J2790 describes an injection of Rho(D) immune globulin, human, full dose, 300 micrograms (1500 I.U.). This product is a human-derived immunoglobulin used to prevent Rh isoimmunization in Rh-negative individuals exposed to Rh-positive red blood cells.
Service type: Therapeutic/prophylactic intramuscular injection of immune globulin.
Typical site of service: Outpatient clinic, hospital outpatient department, emergency department, or other ambulatory care settings where intramuscular injections and postpartum or antenatal care are provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an Rh‑negative pregnant woman who presents for routine prenatal care at 28 weeks' gestation or after a potential sensitizing event (for example, abdominal trauma, threatened abortion, chorionic villus sampling, amniocentesis, or external cephalic version). The clinician documents maternal Rh(D) negative status and either a negative antibody screen or a need for prophylaxis following an exposure. The clinical workflow includes verification of maternal and paternal Rh status, performance of a maternal antibody screen, calculation of Kleihauer–Betke or fetal‑maternal hemorrhage assay if indicated, and administration of J2790 as intramuscular injection (full dose, 300 mcg/1500 IU) in the deltoid or gluteal muscle. Observation for immediate adverse reaction occurs for 15–30 minutes post‑injection. Documentation includes indication (routine prophylaxis at 28 weeks, postpartum prophylaxis within 72 hours, or post‑exposure prophylaxis), lot number, route, dose, site of administration, maternal vitals, and informed consent for the product.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard procedure code | Rarely used; indicates no distinct modifier applicable when billing J‑codes per payer rules. |